Company Analysis Zymergen Inc.
1. Summary
Advantages
- Price (2.43 $) is less than fair price (2.69 $)
- The stock's return over the last year (0%) is higher than the sector average (-12.5%).
Disadvantages
- Dividends (0%) are below the sector average (0.541%).
- Current debt level 39.51% has increased over 5 years from 34.36%.
- The company's current efficiency (ROE=-113.14%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Zymergen Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | 2.5% | 0.7% |
| 90 days | 0% | -17.8% | 2.2% |
| 1 year | 0% | -12.5% | 26% |
ZY vs Sector: Zymergen Inc. has outperformed the "Healthcare" sector by 12.5% over the past year.
ZY vs Market: Zymergen Inc. has significantly underperformed the market by -25.98% over the past year.
Stable price: ZY is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ZY with weekly volatility of 0% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (2.43 $) is lower than the fair price (2.69 $).
Price not significantly lower than the fair price: The current price (2.43 $) is slightly lower than the fair price by 10.7%.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (48.77).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (49.04).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.07) is lower than that of the sector as a whole (4.83).
P/BV vs Market: The company's P/BV (1.07) is lower than that of the market as a whole (3.17).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (17.74) is lower than that of the sector as a whole (33.77).
P/S vs Market: The company's P/S indicator (17.74) is higher than that of the market as a whole (10.24).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (0.0868) is higher than that of the sector as a whole (-22.17).
EV/Ebitda vs Market: The company's EV/Ebitda (0.0868) is lower than that of the market as a whole (28.32).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 7.86% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (7.86%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (4135.44%).
5.4. ROE
ROE vs Sector: The company's ROE (-113.14%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (-113.14%) is lower than that of the market as a whole (10.71%).
5.5. ROA
ROA vs Sector: The company's ROA (-73.48%) is lower than that of the sector as a whole (0.3443%).
ROA vs Market: The company's ROA (-73.48%) is lower than that of the market as a whole (6.47%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-48.71%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-48.71%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.541%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 02.09.2022 | Serber Zachariah Chief Science Officer |
Sale | 2.21 | 7 222 | 3 268 |
| 02.09.2022 | Kim Mina Chief Legal Officer |
Sale | 2.21 | 7 536 | 3 410 |
| 02.09.2022 | Singh Enakshi Chief Financial Officer |
Sale | 2.21 | 8 681 | 3 928 |
| 11.08.2022 | Serber Zachariah Chief Science Officer |
Sale | 3.91 | 21 251 | 5 435 |
| 02.06.2022 | Serber Zachariah Chief Science Officer |
Sale | 1.68 | 4 724 | 2 812 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
